# Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

> **NCT00108108** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** HCD122

## Key facts

- **NCT ID:** NCT00108108
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Slow enrollment and minimal preliminary biological and clinical efficacy.
- **Last updated:** 2012-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108108, "Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00108108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*